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Abstract Urea cycle disorders (UCDs) are inherited disor-
ders of ammonia detoxification often regarded as mainly of
relevance to pediatricians. Based on an increasing number of
case studies it has become obvious that a significant number
of UCD patients are affected by their disease in a non-
classical way: presenting outside the newborn period,
following a mild course, presenting with unusual clinical
features, or asymptomatic patients with only biochemical
signs of a UCD. These patients are surviving into adoles-
cence and adulthood, rendering this group of diseases clini-
cally relevant to adult physicians as well as pediatricians. In
preparation for an international workshop we collected data
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on all patients with non-classical UCDs treated by the par-
ticipants in 20 European metabolic centres. Information was
collected on a cohort of 208 patients 50% of which were ≥ 16
years old. The largest subgroup (121 patients) had X-linked
ornithine transcarbamylase deficiency (OTCD) of whom 83
were female and 29% of these were asymptomatic. In index
patients, there was a mean delay from first symptoms to
diagnosis of 1.6 years. Cognitive impairment was present
in 36% of all patients including female OTCD patients (in
31%) and those 41 patients identified presymptomatically
following positive newborn screening (in 12%). In conclu-
sion, UCD patients with non-classical clinical presentations
require the interest and care of adult physicians and have a
high risk of neurological complications. To improve the
outcome of UCDs, a greater awareness by health profes-
sionals of the importance of hyperammonemia and UCDs,
and ultimately avoidance of the still long delay to correctly
diagnose the patients, is crucial.
Introduction
Urea cycle disorders (UCDs) comprise a group of inherited
defects of amino acid metabolism with an estimated cumula-
tive incidence of 1:8000 to 1:44,000 (Brusilow and Horwich
2001; Brusilow and Maestri 1996; Dionisi-Vici et al 2002;
Wilcken 2004). Normal function of the urea cycle requires
six enzymes: N-acetylglutamate synthase (NAGS), carbamoyl
phosphate synthetase I (CPS1), ornithine transcarbamylase
(OTC), argininosuccinate synthetase (ASS), argininosuccinate
lyase (ASL) and arginase (ARG1). UCDs have been described
resulting from the deficiency of each of these enzymes.
In addition, two transporters are also necessary, because the
metabolic steps are in two cellular compartments: the ornithine/
citrulline antiporter ORNT1, deficiency of which causes
hyperornithinemia-hyperammonemia-homocitrullinuria syn-
drome and the glutamate/aspartate antiporter citrin, deficiency
of which gives rise to citrullinemia type 2.
Although partially expressed in many tissues, the entire
urea cycle pathway is only active in periportal hepatocytes
(Brusilow 1984; Brusilow and Maestri 1996; Davis and Wu
1998; Häussinger 1990). The main function of the urea cycle
is the detoxification of ammonia but it is also the only
pathway for endogenous synthesis of arginine (Brusilow
1984). Defects of the urea cycle result in hyperammonemia.
Hyperammonemia causes encephalopathy which can progress
rapidly from minor, non-specific symptoms through delirium
to deep coma and death due to cerebral oedema (Bachmann
2002; Enns 2008; Msall et al 1984). Chronic encephalopathy
is also seen (Häberle et al 2012; Leonard and Morris 2002;
Nassogne et al 2005; Summar et al 2008). Clinical symptoms
can vary and include recurrent vomiting, lethargy, personality
change, agitation, protein avoidance, seizures and coma. In
some patients the initial presentation is psychiatric. Prognosis
mainly depends on the severity, duration and frequency of
hyperammonemic decompensations, although significant cog-
nitive impairment can occur even after a single episode of
metabolic decompensation. In some patients the likely out-
come can at least be predicted from the underlying molecular
defect (Berning et al 2008; Ficicioglu et al 2009; Häberle et al
2003; Häberle et al 2011; Mercimek-Mahmutoglu et al
2010; Msall et al 1984; Picca et al 2001). Inheritance of
all UCDs is autosomal recessive, except for OTC deficiency
(OTCD), themost frequent UCD, which is X-linked (Tuchman
1992).
UCDs classically manifest themselves in the neonatal
period but in fact can present at any age (Lee et al 2005;
Lee 2006; Legras et al 2002; Leonard and Morris 2002;
Nassogne et al 2005; Summar et al 2008). Non-classical
UCDs with atypical clinical courses extend the spectrum of
UCDs. This has been documented in several case reports and
small case series but not yet in a cohort or larger observa-
tional study.
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In 2011, in an International workshop “Non-classical
Urea Cycle Disorders” held in Zurich focussing on non-
classical forms of UCDs, we tried to fill this gap by
collecting data from UCD patients with atypical features:
onset after the newborn period; a mild disease course; un-
common presentations (at any age); asymptomatic individuals
(screened because of affected relatives or identified through
newborn screening, NBS) with biochemical features of a
UCD. Participants from 20 metabolic centres in five
European countries shared their experience on non-classical
UCD patients and critically discussed how they should be
managed. The primary aim of the workshop, and of this
publication, was to collect and to present data on the number
of patients with and the clinical course of non-classical UCDs,
to improve awareness of this group of patients and to discuss
suggestions for their management. Focus of the presented data
is on the most important aspects of diagnosis, clinical course,
and therapy.
Methods
Study population
Contributing centres cared for a significant number of patients
ensuring a high level of experience and standard of care.
Participants came from four centres in Austria (Bregenz,
Graz, Innsbruck and Vienna), nine in Germany (Berlin,
Düsseldorf, Freiburg, Hamburg, Hannover, Heidelberg,
Leipzig, München, Münster), two in The Netherlands
(Amsterdam/Utrecht and Rotterdam), four in Switzerland
(Basel, Bern, Lausanne and Zurich) and one in the United
Kingdom (London). All patients included in this study met at
least one of the following criteria:
1. presentation after the newborn period
2. an unusually mild course with absence of metabolic
decompensations
3. an uncommon presentation with signs and symptoms not
frequently reported in UCDs (either in the newborn
period or beyond)
4. having biochemical features of a UCD but no clinical
symptoms.
Data were obtained from each centre on number of pa-
tients, type of UCD, mode of diagnosis, clinical course,
treatment and outcome. Additional diagnoses were collected
as free text. Prior to data collection, an electronic data sheet
was pilot-tested in one centre (Zurich) for ease of use,
followed by some adjustments. In most centres, data were
collected by a trained medical student together with the local
metabolic specialist using patients’ records as the source of
information. Data were anonymised prior to evaluation and
statistical analysis.
Statistics
Data were transferred to IBM SPSS statistics version
20 (IBM, New York) and analysed with the applica-
tions “crosstabulation”, “frequency” and “mean”. Chi-
square and t-tests were used for significance testing.
The present investigation was designed as an explor-
ative study. Significance level was set at 0.05 and not
adjusted for multiple testing. For diagrams, we used
Microsoft Office Excel 2007 and 2010 (Microsoft
Corporation, Redmond).
Results
Patients and diagnoses
Data from 208 non-classical UCD patients with deficiencies
of OTC (121; 58%), ASS (ASSD; 43; 20%), ASL (ASLD;
31; 15%), ARG1 (ARG1D; 8; 4%), CPS1 (CPS1D; 2; 1%),
NAGS (NAGSD; 1; 1%), and the HHH syndrome (2; 1%)
were collected (Table 1).
Of the 121 OTCD patients, 83 (69%) were female and 38
(31%) were male. In the 87 patients not affected by OTCD
the sex distribution was more even (38 (44%) female and 49
(56%) male patients) (Table 1).
The patients’ age at the time of data collection ranged
from 1 month to 66.5 years (the oldest two being female
patients with OTCD) with a mean of 18.5 years (sd=13.5)
for the entire cohort. Of them, 103 (50%) were<16 years of
age (Fig. 1 and Table 2).
Table 1 Basic description of the cohort
Disease Number (% of total) Gender
Female Male
OTCD 121 (58%) 83 (69%) 38 (31%)
ASSD 43 (20%) 22 (51%) 21 (49%)
ASLD 31 (15%) 11 (36%) 20 (64%)
ARG1D 8 (4%) 3 (38%) 5 (62%)
HHH syndrome 2 (1%) 0 2 (100%)
CPS1D 2 (1%) 1 (50%) 1 (50%)
NAGSD 1 (1%) 1 (100%) 0
Total 208 (100%) 121 (58%) 87 (42%)
OTCD ornithine transcarbamylase deficiency; ASSD argininosuccinate
synthetase deficiency; ASLD argininosuccinate lyase deficiency;
ARG1D arginase deficiency; HHH syndrome hyperornithinemia-
hyperammonemia-homocitrullinuria syndrome; CPS1D carbamoyl
phosphate synthetase I deficiency; NAGSD N-acetylglutamate synthase
deficiency
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Mode of diagnosis
Mode of diagnosis was available for 202 patients. Just over
half (102; 51%) were index-patients diagnosed due to symp-
toms. Others were diagnosed because of a positive family
history (52; 26%), as part of NBS programmes (41; 20%)
(including only ASSD and ASLD patients, since neonatal
screening was performed for these two diseases only) and by
antenatal diagnosis in affected families (7; 3%) (Table 3).
Genetic analysis
From all 208 patients, 141 (68%) had genetic testing
performed. This led to a confirmation of the diagnosis in
126 (89%). In 15 (11%) patients no mutations were found
(13 OTCD patients and two ASLD patients).
Information on the maternal carrier status was available
for 76 (63%) patients with OTCD (57 female and 19 male,
after exclusion of three siblings of index patients). In 33%
(19) of the female and 74% (14) of the male patients the
mother was carrier for OTCD (χ2(df=1)=9.74; p=0.002).
In the group of 43 ASSD patients, genetic testing was
performed and fully informative in 30 (70%). Of these, 15
(50%) patients were shown to be homozygous for one of
three missense mutations known to be associated with
mild citrullinemia type 1 (p.Trp179Arg, p.Val263Met, or
p.Gly362Val) (Häberle et al 2003). Four of these patients (of
which three were identified by NBS) went on to experience
symptomatic hyperammonemia (ammonia levels 146–190
μmol/L) indicating the need for medical follow-up of this
group of patients.
A similar picture can be drawn for ASLD patients of
whom 18 (58%; n=31) had molecular genetic analysis,
yielding the full genotype in all but two patients. In six
patients, a homozygous missense mutation (p.Val178Met,
p.Glu189Gly, or p.Arg379Cys) previously associated with
a mild phenotype could be identified (Kleijer et al 2002;
Mercimek-Mahmutoglu et al 2010). As in the ASSD pa-
tients, two of these patients with a supposedly mild genotype
presented with clinical hyperammonemia (ammonia 86 and
175 μmol/L).
Clinical course
Clinical data were available for 205 patients. Asymptomatic
until the age of data collection were 72 (35%) patients. Of
these, 34 (47%) were diagnosed because of a positive
family history, 33 (46%) by NBS programmes (10 ASLD
patients and 23 ASSD patients), and five (7%) by prenatal
screening.
The most frequent diagnosis, in 121 patients, was OTCD
with clinical information available in 118 patients. Of these,
72% (85) had clinical symptoms and 28% (33) were asymp-
tomatic. The proportion of clinically affected patients was
independent of sex with 57 (71%) of female and 28 (74%) of
male OTCD patients having symptoms (χ2(df=1)=0.076;
p=0.78).
Fig. 1 Age distribution of all patients (n=208). Each column in this
graph represents one patient. The line at age 16 is separating pediatric
from adult patients (patient 104 being the first adult)
Table 2 Age distribution of the
cohort, abbreviations as in
Table 1
Disease Mean age in
years (range)
Pediatric patients
(< 16 years)
Adult patients
(≥ 16 years)
OTCD (all) 22.2 (0.1–66.5) 47 (39%) 74 (61%)
OTCD (females) 24.5 (2.2–66.5) 28 (34%) 55 (66%)
Cohort except OTCD 13.4 (0.7–47.0) 56 (64%) 31 (36%)
Cohort except female OTCD 14.5 (0.1–47.0) 75 (60%) 50 (40%)
ASLD 16.8 (1.5–35.8) 14 (45%) 17 (55%)
ASSD 9.0 (0.7–26.8) 35 (81%) 8 (19%)
ARG1D 23.5 (4.2–47.0) 4 (50%) 4 (50%)
HHH syndrome 4.7 (3.0–6.3) 2 (100%) 0
CPS1D 15.5 (8.1–22.9) 1 (50%) 1 (50%)
NAGSD 27.2 0 1 (100%)
Total 18.5 (0.1–66.5) 103 (50%) 105 (50%)
24 J Inherit Metab Dis (2014) 37:21–30
For ASSD, 65% (n=43) of patients were asymptomatic
and for ASLD, 36% (n=31) (χ2(df=1)=6.35; p=0.012)
(Table 3). All patients affected by ARG1D, HHH syndrome,
CPS1D and NAGSD had symptoms at some stage of their
clinical course that were attributed to the underlying bio-
chemical defect (Table 3).
Mean age at first symptoms (not always a decompensation
but any symptom attributed to a UCD) for all symptomatic
patients was 3.6 years (n=115; sd=6.3, range 0.1-35) and
mean age at diagnosis for the entire cohort was 5.9 years
(n=186; sd=10, range 0–55) (Table 3). For patients diagnosed
because of clinical symptoms, the mean delay from first
symptoms to final diagnosis was 1.6 years (n=91; sd=2.8,
range 0–13) (Table 3 and Fig. 2). A prompt diagnosis, within
one month after onset of symptoms, was only made in 36
patients (40%; n=91). A delay of >1 month to 1 year was
observed in 27 patients. In 28 patients, the delay was>1 year.
Symptoms and complications
We systematically collected data on presence of episodes of
symptomatic hyperammonemia, number of hospitalisations,
cognitive impairment (mental retardation (MR) of any sever-
ity (including learning difficulties) and/or developmental
delay (DD)), and presence of seizures.
Data on symptomatic hyperammonemia were available
for 204 (98%; n=208) patients (Fig. 3). At least 106 (52%;
n=204) had one documented episode of symptomatic
hyperammonemia. In female OTCD patients 64% (52;
n=81) had at least one crisis, and in male OTCD patients
71% (27; n=38) (χ2(df=1)=0.81; p=0.37). Median peak
ammonia for all patients with at least one acute crisis
(n=84) was 305 μmol/L (range 60-1300). The highest peak
ammonia was measured in a female OTCD patient. The
median peak ammonia in OTCD females with an acute crisis
(n=36; 381 μmol/L, range 121–1300) was not significantly
different from the median peak ammonia in male OTCD
patients with acute crisis (n=22; 294 μmol/L, range 129–
1077) (Mann–Whitney-U=304; z=−1.474; p=0.14).
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Fig. 2 Diagnostic delay between onset of first symptoms and diagnosis
of a UCD in years for the 91 patients diagnosed because of symptoms.
Each dot represents one patient
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Information on the frequency of hospitalisations (“never”,
“once”, “twice or more”) for acute hyperammonemic crises
or beginning/imminent hyperammonemia was available for
202 (97%) patients: 93 (46%) were never hospitalised, 30
(15%) once, and 79 (39%) twice or more often. In OTCD
(n=121) 23 (20%) had one and 56 (48%) had two or more
hospitalisations. In ASLD and ASSD, 23 (74%; n=31) and
31 (74%; n=43), respectively, never required hospitalisation.
In the entire cohort (n=208 patients), 74 (36%) had a diag-
nosis of MR/DD (Fig. 3). In the subgroup of OTCD patients
(n=121), 37 were affected by MR/DD (corresponding to 31%
of all and 44% of the symptomatic patients). In ASLD, all of the
symptomatic patients (n=20) were indeed affected byMR/DD;
three of the ASLD patients with MR/DD were found by NBS.
In ASSD, seven (16%) suffered fromMR/DD including two of
the patients found by NBS (carrying the homozygous mutation
p.Trp179Arg and the heterozygous mutations p.Arg272Leu
and Ivs13+5G>A, respectively). MR/DD was present in the
HHH syndrome in one (50%), in NAGSD in none (0%) and in
CPS1D in two (100%) patients, respectively.
If there was a diagnostic delay of >1 year (arbitrarily set
cut-off), as occurred in 28 patients, 75% (21) of patients were
affected by MR/DD while only 46% (29) of 63 patients were
affected byMD/DD if the delay was ≤1 year (χ2(df=1)=6.92;
p<0.01).
Seizures were present in 37 (18%) patients at some point.
Patients affected by ARG1D had the highest incidence of
seizures (7 patients; 88%), followed by ASLD (7; 23%),
OTCD (18; 15%) and ASSD (4; 9%). Seizures have not been
reported for the few patients with HHH syndrome and
NAGSD in this study.
Additional symptoms collected as free text included
hepatopathy/liver failure (total, n=20; OTCD, n=11; ASLD,
n=6; ASSD, n=2; HHH syndrome, n=1), hepatomegaly
(total, n=4; OTCD, n=2; ASLD, n=2), elevated transami-
nases (total, n=6; OTCD, n=5; ASSD, n=1), behavioural
problems (n=16), obesity (n=8), psychiatric symptoms
(n=6), spasticity (n=5, four affected by ARG1D, one by
OTCD), headache (n=5), feeding problems (n=5),
trichorrhexis nodosa (n=5, all ASLD), hyperlipidemia
(hypertriglyceridemia and/or hypercholesterolemia) (n=4),
ataxia (n=4), muscular hypotonia (n=4), and diabetes mellitus
type 1 (n=3).
Symptoms and complications in patients diagnosed
by newborn screening
Diagnosed in NBS programmes were 67% of ASSD
patients (28; n=43) and 43% of ASLD (13; n=31)
(Table 3).
In ASSD, 18% (5; n=28) of patients were symptomatic if
detected by NBS (called thereafter “NBS-patients”), versus
64% (9; n=15) of patients found by selective screening (i.e.
index patients diagnosed because of clinical symptoms, due
to positive family history or prenatal screening, called there-
after “non-NBS-patients”) (χ2(df=1)=9.05; p=0.003). An
episode of symptomatic hyperammonemia was observed in
18% (5; n=28) of NBS- patients and 57% (8) of non-NBS-
patients (χ2(df=1)=6.74; p=0.009). MR/DDwas seen in 7%
(2) of NBS-patients and 29% (4) of non-NBS-patients
(χ2(df=1)=3.50; p=0.061) and seizures were reported in
only one NBS patient (4%) but 21% (3) of non-NBS-
patients (χ2(df=1)=3.45; p=0.063).
In ASLD, 23% (3; n=13) of NBS-patients were symp-
tomatic, versus 94% (16; n=18) of non-NBS patients
(χ2(df=1)=16.01; p=0.000). An episode of symptomatic
hyperammonemia was reported in one of the NBS-patients
(8%) but in five of the non-NBS-patients (31%) (χ2(df=1)=2.43;
p=0.119). MR/DD was seen in 23% (3) of NBS-patients and
94% (16) of non-NBS-patients (χ2(df=1)=16.01; p=0.000) and
seizures were reported in 41% (7) of non-NBS-patients but not in
NBS-patients (χ2(df=1)=4.97; p=0.026).
Dietary treatment
For all but one patient, nutritional data were available. A
protein restricted diet was prescribed for 120 (58%; n=207)
of the patients and a self chosen vegetarian diet and/or
protein avoidance were reported as “additional information”
in 16 patients. Of the 133 symptomatic patients, 109 (82%)
were protein restricted versus 10 (14%) of the 71 asymptom-
atic patients. Of those treated with protein restriction, only 87
(73%) received supplements of vitamins and/or essential
amino acids.
We did not systematically collect information on the
compliance of the patients.
Fig. 3 Frequency of acute crisis in each disease (OTCD, ASSD, ASLD
and ARG1D, as well as total including HHH syndrome, NAGSD,
CPS1D) (data from 204 patients) and the proportions of MR/DD (data
from 208 patients)
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Nitrogen scavenger drugs and L-citrulline and L-arginine
supplementation
Data on current pharmacological treatment were available in
most patients (concerning use of nitrogen scavenger drugs
and L-citrulline and/or L-arginine supplementation in 196
and 199 patients, respectively (Table 4 and Fig. 4a, b)).
We did not systematically collect information on the
compliance of the patients.
Liver transplantation
Liver transplantation, currently the only ‘cure’ for UCDs,
was performed in only six (3%; n=208) patients including
four females with OTCD and two with ASSD (1F, 1M).
Mortality
Of all 208 patients, six (3%) had already died (all affected by
OTCD) (Table 3). One patient died at 8.9 years during an
acute crisis, one at the age of 5.3 years from brain edema, one
at 12 years from abdominal bleeding and post transplantation
liver failure, one at 10 years due to brain edema during an
infection, one committed suicide at 33 years, and one patient
died at 22 years without documentation of the cause.
Discussion
Most metabolic centres care for only small groups of UCD
patients and large registries have only recently been
established (Kölker et al 2011; Tuchman et al 2008).
Therefore, information on the natural course of these dis-
eases has mainly relied on case reports and case series.
Traditionally, UCDs are considered as pediatric diseases
and only few publications focus on adult presentations
(Bogdanovic et al 2000; Felig et al 1995; Honeycutt et al
1992; Maestri et al 1998; Salek et al 2010; Saudubray et al
2006; Schimanski et al 1996; Smith et al 2005; Snebold et al
1987; Thurlow et al 2010).
However with improvements in management, more
UCD patients are reaching adulthood. In recent years it
has become obvious that non-classical UCD patients with
later onset and/or an attenuated clinical course may be as
Table 4 Nitrogen scavenger drugs and L-citrulline and L-arginine
Patients (clinical course) Nitrogen scavenger drugs (n=196) L-citrulline and L-arginine supplementation (n=199)
SB SP SD & SP None Total Arg Cit Cit & Arg None Total
Asymptomatic 3 (5%) 1 (1%) 3 (5%) 57 (89%) 64 (100%) 18 (27%) 5 (8%) 3 (4%) 41 (61%) 67 (100%)
Symptomatic 41 (31%) 25 (19%) 29 (22%) 36 (28%) 131 (100%) 68 (52%) 37 (28%) 7 (5%) 19 (15%) 131 (100%)
Unknown 1 – – – 1 1 – – – 1
Total 45 (23%) 26 (13%) 32 (16%) 93 (48%) 196 (100%) 87 (44%) 42 (21%) 10 (5%) 60 (30%) 199 (100%)
Data on treatment with nitrogen scavenger drugs and L-citrulline and L-arginine supplementation for patients with asymptomatic, symptomatic or
unknown clinical courses
SB sodium benzoate; SP sodium phenylbutyrate; Cit L-citrulline; Arg L-arginine
Fig. 4 Pharmacological treatment with Na-Benzoate and Na-
Phenylbutyrate (4a) (data from 196 patients) as well as supplements
of L-arginine and L-citrulline (4b) (data from 199 patients)
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frequent as those with classical presentations in the first
weeks of life.
Data on patients with an atypical presentation, as defined
above, were therefore collected from metabolic centres from
five European countries. The resulting cohort of 208 patients
was discussed in a workshop on non-classical UCDs held in
2011. It is important to notice that even with strict adherence
to the given criteria, this study is descriptive and contains
some ascertainment bias. Moreover, the definition of “non-
classical UCDs” is not listed in accepted classifications such
as ICD10 and this may be another confounding factor.
Similar numbers of pediatric and adult patients were
present in this cohort (103 and 105, respectively). When
OTCD patients were excluded from the analysis, the age
distribution was slightly in favour of pediatric patients
(64%). However in the largest subgroup, OTCD patients,
the majority were adult (61%) with a mean age of 24.5 years
in female and 17.1 years in male OTCD patients, underlining
the need for physicians experienced in treating adult patients
with UCDs.
Based on the high proportions of symptomatic cases
(71%), female OTCD should not be regarded a benign dis-
order, although there may be a bias in this cohort towards
symptomatic females because asymptomatic female carriers
may not have come to clinical attention.
In our sample, equal proportions of female and male
OTCD patients were symptomatic and also the proportion
of male and female patients with at least one documented
episode of symptomatic hyperammonemia was not statisti-
cally different. Likewise, the median peak ammonia for
OTCD females with acute crisis (381 μmol/L) was not
significantly different from that in male patients (294
μmol/L). Overall, the number of symptomatic patients was
highest in OTCD (72% of all patients) compared to 65% in
ASLD and 35% in ASSD. However this difference is prob-
ably explained by asymptomatic ASLD and ASSD patients
identified by NBS.
Confirming data from other reports (Genet et al 2000;
Yamaguchi et al 2006), the mutation detection rate in this
study for OTCD was 84%, whereas it reached 97% in other
UCDs. Also in line with published data (Tuchman et al
1995), maternal carrier status for OTCD was more common
in male OTCD (74%) than in female OTCD (33%). This
higher risk for mothers of boys to have another affected child
is important for genetic counselling.
The diagnostic delay observed in this cohort is worrying
albeit similar to other inborn errors of metabolism and
confirming previous reports (Rowe et al 1986). In the group
of patients with a delay of >1 year, 75% were affected by
cognitive impairment compared to 46% if the delay was
≤1 year. Assuming that severe cases reach their confirmed
diagnosis earlier, this higher proportion of cognitive impair-
ment in the presumably less severely affected patients
suggests a causative relationship of time to diagnosis and
likelihood of cognitive impairment. Although this finding
would ideally be confirmed in larger studies, this is in favour
of a need for prompt diagnosis and initiation of treatment to
avoid a poor neurological outcome. If this is to be achieved,
there needs to be an increased awareness of the possibility of
a UCD and ammonia should be measured early in every
patient with unexplained clinical features compatible with a
UCD such as impaired consciousness, liver failure, or psy-
chiatric symptoms.
A larger proportion of ASLD and ASSD patients detected
by NBS as compared to those without NBS remained asymp-
tomatic, in line with previous reports on the benign course in
some patients (Ficicioglu et al 2009; Häberle et al 2003;
Mercimek-Mahmutoglu et al 2010). However, some patients
identified through NBS later developed symptomatic
hyperammonemia. Of those, some carried a genotype
predicting a “mild course” indicating that the clinical man-
agement can not entirely rely on genotypes only. This un-
derlines the need to follow these patients regularly in a
metabolic centre and to provide a sick-day protocol and
emergency regimen to cover potentially catabolic episodes.
A high number of patients were affected by MR/DD in the
entire cohort but especially in ASLD and ARG1D, with all
ASLD patients being symptomatic and 88% of ARG1D
patients. This poor outcome might in part be caused by the
longer mean diagnostic delay in ASLD (3 years, sd=4, range
0–13) and ARG1D (2.5 years, sd=1.7, range 0–4) patients
compared to OTCD (1.2 years, sd=2.4, range 0–9.5) al-
though symptoms in ARG1D are in addition caused by its
specific pathogenesis. However, more detailed information
about the neurological situation of UCD patients would be
required before final conclusions can be drawn. The same
refers to the relatively small number of patients with seizures
(except in the few ARG1D patients of which 88% were
affected). The reason for this might be the inclusion of
asymptomatic patients or those with mild phenotypes.
Regarding treatment, it is interesting to see that the same
number of OTCD patients was treated with either L-citrulline
39 (35%) or with L-arginine 40 (36%) and only few patients
received both (Fig. 4b). This reflects the unsolved issue of
using L-citrulline or L-arginine alone or a combination of
both (Häberle et al 2012; Wilcken 2004). The choice of L-
arginine might be influenced by the higher price and the
lower availability of L-citrulline but further studies are re-
quired to determine whether one amino acid is superior to the
other in treating OTCD.
In summary, this cross-sectional observational report on a
large cohort of patients with non-classical UCDs highlights
the high proportion of adult patients, of clinically affected
female OTCD patients and of cognitive impairment as well
as the often long delay in reaching the correct diagnosis that
may add to a relevant extent to the morbidity of the cohort.
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There is a need for greater awareness that these disorders can
present in a non-classical way and outside the neonatal period.
Longitudinal studies are required to determine the long-term
outcome for this growing group of patients.
Clues for clinical practice
•Urea cycle disorders (UCDs) may be important also for adult
physicians since in this study 50% of the patients were ≥
16 years old
• The diagnosis should be made as early as possible to avoid
neurological complications; in this study 75% were
affected by cognitive impairment if the delay was >1 year,
compared to 46% if the delay was ≤ 1 year
• In all patients with unexplained acute encephalopathy,
plasma ammonia should be measured
• If neurological symptoms are episodic and variable,
consider an underlying UCD
• Include UCDs to the differential diagnosis in patients with a
suspicion of an intoxication
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